Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Aptevo Therapeutics ( (APVO) ) is now available.
On March 10, 2026, Aptevo Therapeutics reported new interim data from two trials of its lead candidate mipletamig, used in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients who are elderly or unfit for intensive chemotherapy. Among 28 evaluable frontline patients, the regimen delivered an 86% clinical benefit rate, 79% complete or near-complete remissions, and no cases of cytokine release syndrome, suggesting a differentiated safety and efficacy profile versus current standards of care.
The company highlighted that more than half of complete responders reached measurable residual disease-negative status and that four patients were able to proceed to allogeneic stem cell transplant, an outcome rarely seen in this fragile population. These results strengthen mipletamig’s positioning as a potentially combinable, lower-toxicity add-on to existing AML frontline therapy and support continued advancement of the RAINIER Phase 1b/2 trial as Aptevo seeks to establish a long-term role for the drug in treating high-risk AML patients.
The most recent analyst rating on (APVO) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Aptevo Therapeutics stock, see the APVO Stock Forecast page.
Spark’s Take on APVO Stock
According to Spark, TipRanks’ AI Analyst, APVO is a Neutral.
The score is held down primarily by very weak financial performance (no revenue, large ongoing losses, and heavy cash burn) and a strong technical downtrend. Offsetting this somewhat are positive corporate events—extended financing runway and encouraging trial results—while valuation offers limited support due to the company’s loss-making profile.
To see Spark’s full report on APVO stock, click here.
More about Aptevo Therapeutics
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for cancer. Its pipeline includes two clinical and six preclinical candidates targeting a range of solid tumors, all built on its proprietary ADAPTIR and ADAPTIR-FLEX platforms, with a stated mission to improve outcomes for cancer patients.
Average Trading Volume: 192,076
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.19M
Find detailed analytics on APVO stock on TipRanks’ Stock Analysis page.